Skip to main content
Top
Published in: Supportive Care in Cancer 12/2015

01-12-2015 | Original Article

What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer

Authors: Thomas W. LeBlanc, Myles Nickolich, Christel N. Rushing, Gregory P. Samsa, Susan C. Locke, Amy P. Abernethy

Published in: Supportive Care in Cancer | Issue 12/2015

Login to get access

Abstract

Purpose

Patients with advanced non-small cell lung cancer (aNSCLC) face a significant symptom burden. Little is known about the frequency and severity of symptoms over time, so we longitudinally characterized patients’ symptoms using the Patient Care Monitor (PCM) version 2.0, an electronic symptom-assessment tool.

Methods

Ninety-seven patients with aNSCLC completed the PCM at up to four clinic visits. We analyzed symptom data by incidence, severity, type (functional vs. nonfunctional), proximity to death, and cancer anorexia-cachexia syndrome status (CACS).

Results

Functional concerns predominated, even in the non-CACS group. Average severity among the top 5 symptoms was worse for functional than nonfunctional items (mean difference 0.62, 95 % CI 0.22–1.01, P = 0.003). Severe dyspnea and fatigue were the most prevalent nonfunctional symptoms; moderate/severe dyspnea was reported by at least 29 % of patients, and fatigue by over 50 %. Depression was reported infrequently, with over half of patients at each visit reporting “none”; moderate or severe depression was reported in only 2.5–9.3 and 3.4–6.2 % of patients, respectively. The average number of moderate/severe symptoms increased with proximity to death; 84 % reported moderate/severe fatigue in the last 3 months of life, compared to 48 % at ≥12 months from death (P = 0.007).

Conclusions

Patients with aNSCLC face a significant symptom burden, which increases with proximity to death. Symptom type and severity vary by proximity to death, but even patients without overt CACS report significant functional symptoms throughout. We recommend an individualized approach to palliative symptom intervention in advanced lung cancer, based on detailed symptom assessment and tracking.
Literature
1.
go back to reference Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742. doi:10.1056/NEJMoa1000678 CrossRefPubMed Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742. doi:10.​1056/​NEJMoa1000678 CrossRefPubMed
4.
go back to reference Degner LF, Sloan JA (1995) Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manag 10(6):423–431CrossRef Degner LF, Sloan JA (1995) Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manag 10(6):423–431CrossRef
5.
go back to reference Yang P, Cheville AL, Wampfler JA, Garces YI, Jatoi A, Clark MM, Cassivi SD, Midthun DE, Marks RS, Aubry MC, Okuno SH, Williams BA, Nichols FC, Trastek VF, Sugimura H, Sarna L, Allen MS, Deschamps C, Sloan JA (2012) Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol 7(1):64–70. doi:10.1097/JTO.0b013e3182397b3e PubMedCentralCrossRefPubMed Yang P, Cheville AL, Wampfler JA, Garces YI, Jatoi A, Clark MM, Cassivi SD, Midthun DE, Marks RS, Aubry MC, Okuno SH, Williams BA, Nichols FC, Trastek VF, Sugimura H, Sarna L, Allen MS, Deschamps C, Sloan JA (2012) Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol 7(1):64–70. doi:10.​1097/​JTO.​0b013e3182397b3e​ PubMedCentralCrossRefPubMed
7.
go back to reference Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol 24(24):3831–3837. doi:10.1200/JCO.2006.05.8073 CrossRefPubMed Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol 24(24):3831–3837. doi:10.​1200/​JCO.​2006.​05.​8073 CrossRefPubMed
8.
go back to reference Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. doi:10.1056/NEJMoa061884 CrossRefPubMed Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550. doi:10.​1056/​NEJMoa061884 CrossRefPubMed
11.
go back to reference Thavarajah N, Chen E, Zeng L, Bedard G, Di Giovanni J, Lemke M, Lauzon N, Zhou M, Chu D, Chow E (2012) Symptom clusters in patients with metastatic cancer: a literature review. Expert Rev Pharmacoecon Outcomes Res 12(5):597–604. doi:10.1586/erp.12.41 CrossRefPubMed Thavarajah N, Chen E, Zeng L, Bedard G, Di Giovanni J, Lemke M, Lauzon N, Zhou M, Chu D, Chow E (2012) Symptom clusters in patients with metastatic cancer: a literature review. Expert Rev Pharmacoecon Outcomes Res 12(5):597–604. doi:10.​1586/​erp.​12.​41 CrossRefPubMed
12.
go back to reference Chen E, Nguyen J, Cramarossa G, Khan L, Leung A, Lutz S, Chow E (2011) Symptom clusters in patients with lung cancer: a literature review. Expert Rev Pharmacoecon Outcomes Res 11(4):433–439. doi:10.1586/erp.11.56 CrossRefPubMed Chen E, Nguyen J, Cramarossa G, Khan L, Leung A, Lutz S, Chow E (2011) Symptom clusters in patients with lung cancer: a literature review. Expert Rev Pharmacoecon Outcomes Res 11(4):433–439. doi:10.​1586/​erp.​11.​56 CrossRefPubMed
15.
go back to reference Reese JB, Shelby RA, Abernethy AP (2011) Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. Support Care Cancer: Off J Multinat Assoc Support Care Cancer 19(1):161–165. doi:10.1007/s00520-010-1000-0 CrossRef Reese JB, Shelby RA, Abernethy AP (2011) Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. Support Care Cancer: Off J Multinat Assoc Support Care Cancer 19(1):161–165. doi:10.​1007/​s00520-010-1000-0 CrossRef
17.
go back to reference Abernethy AP, Herndon JE 2nd, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lyerly HK (2009) Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manag 37(6):1027–1038. doi:10.1016/j.jpainsymman.2008.07.011 CrossRef Abernethy AP, Herndon JE 2nd, Wheeler JL, Day JM, Hood L, Patwardhan M, Shaw H, Lyerly HK (2009) Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. J Pain Symptom Manag 37(6):1027–1038. doi:10.​1016/​j.​jpainsymman.​2008.​07.​011 CrossRef
19.
go back to reference Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE 2nd (2010) Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manag 40(4):545–558. doi:10.1016/j.jpainsymman.2010.01.017 CrossRef Abernethy AP, Zafar SY, Uronis H, Wheeler JL, Coan A, Rowe K, Shelby RA, Fowler R, Herndon JE 2nd (2010) Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. J Pain Symptom Manag 40(4):545–558. doi:10.​1016/​j.​jpainsymman.​2010.​01.​017 CrossRef
21.
go back to reference Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. doi:10.1016/S1470-2045(10)70218-7 CrossRefPubMed Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. doi:10.​1016/​S1470-2045(10)70218-7 CrossRefPubMed
22.
go back to reference Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18(4):893–903PubMed Hopwood P, Stephens RJ (2000) Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 18(4):893–903PubMed
24.
go back to reference van den Dungen IA, Verhagen CA, van der Graaf WT, van den Berg JP, Vissers KC, Engels Y (2014) Feasibility and impact of a physical exercise program in patients with advanced cancer: a pilot study. J Palliat Med 17(10):1091–1098. doi:10.1089/jpm.2013.0638 CrossRefPubMed van den Dungen IA, Verhagen CA, van der Graaf WT, van den Berg JP, Vissers KC, Engels Y (2014) Feasibility and impact of a physical exercise program in patients with advanced cancer: a pilot study. J Palliat Med 17(10):1091–1098. doi:10.​1089/​jpm.​2013.​0638 CrossRefPubMed
25.
go back to reference Temel JS, Currow DC, Fearon K, Gleich L, Yan Y, Friend J, Abernethy AP (2014) Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: results from the phase 3 studies ROMANA 1 and 2. Ann Oncol 24 (suppl 4):doi: 10.1093/annonc/mdu1438.1062 Temel JS, Currow DC, Fearon K, Gleich L, Yan Y, Friend J, Abernethy AP (2014) Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: results from the phase 3 studies ROMANA 1 and 2. Ann Oncol 24 (suppl 4):doi: 10.​1093/​annonc/​mdu1438.​1062
Metadata
Title
What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer
Authors
Thomas W. LeBlanc
Myles Nickolich
Christel N. Rushing
Gregory P. Samsa
Susan C. Locke
Amy P. Abernethy
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2699-4

Other articles of this Issue 12/2015

Supportive Care in Cancer 12/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine